Chin Hur
YOU?
Author Swipe
View article: Clinical utility of EHR-based predictive models for identifying high-risk individuals in early cancer detection
Clinical utility of EHR-based predictive models for identifying high-risk individuals in early cancer detection Open
Electronic health records (EHRs) offer a promising, scalable approach for identifying individuals at high risk for targeted cancer screening, but the absence of clinical benchmarks has limited their adoption. We evaluated the clinical util…
View article: Upper Endoscopy Is Associated With Reduced Gastric Cancer-Specific and Overall Mortality in Patients Undergoing Colonoscopy or Sigmoidoscopy
Upper Endoscopy Is Associated With Reduced Gastric Cancer-Specific and Overall Mortality in Patients Undergoing Colonoscopy or Sigmoidoscopy Open
View article: Cost-Effectiveness of Endoscopic Stricturotomy Versus Resection Surgery for Crohn’s Disease Strictures
Cost-Effectiveness of Endoscopic Stricturotomy Versus Resection Surgery for Crohn’s Disease Strictures Open
Background: Endoscopic therapies for Crohn’s disease (CD) strictures, including endoscopic balloon dilation (EBD) and endoscopic stricturotomy (ESt), are less invasive interventions compared to surgery. ESt is advantageous for strictures t…
View article: Enhancing EHR-based pancreatic cancer prediction with LLM-derived embeddings
Enhancing EHR-based pancreatic cancer prediction with LLM-derived embeddings Open
View article: Supplemental Table 1 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 1 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 1: Model characteristics.
View article: Supplemental Figure 1 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Figure 1 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Figure 1: Projected age adjusted uterine cancer incidence and incidence-based mortality among women aged 40+ stratified by race and ethnicity to 2050.
View article: Supplemental Table 7 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 7 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 7: Observed and predicted stage distribution for uterine cancer.
View article: Supplemental Table 3 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 3 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 3: Variables available to define extent of disease and AJCC stage.
View article: Supplemental Table 4 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 4 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 4: Transition bounds within the model.
View article: Supplemental Table 6 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 6 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 6: Maximum clinical incidence reduction (MCLIR) scenario analyses.
View article: Supplemental Table 8 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 8 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 8: Observed and predicted uterine cancer incidence-based mortality.
View article: Supplemental Table 2 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 2 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 2: Histologic groupings from SEER 18.
View article: Supplemental Table 5 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 5 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 5: Objective function inputs.
View article: Supplemental Table 9 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 9 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Supplemental Table 9: Observed and projected incidence and 5-year survival of uterine cancer overall and stratified by histology with projected trends in obesity and hysterectomy rates.
View article: Data from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Data from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States Open
Background:To develop a natural history model for uterine cancer calibrated to population-based incidence and mortality data to project future trends in the disease through 2050.Methods:We developed a state-transition microsimulation model…
View article: Estimated Costs and Cost-Effectiveness of a Pediatric Weight Management Program
Estimated Costs and Cost-Effectiveness of a Pediatric Weight Management Program Open
Importance Childhood obesity remains a significant public health challenge, with ongoing racial, ethnic, and socioeconomic disparities in its prevention and treatment. Economic evaluations of pediatric obesity interventions are essential f…
View article: Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery
Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery Open
Glucagon-like-peptide-1 (GLP-1) receptor agonists are approved for the treatment of type II diabetes mellitus and obesity. These agents slow gastric emptying and may increase the risk of pulmonary aspiration, particularly in patients under…
View article: Recent US Gastric Cancer Prevention Recommendations: Advances, Unanswered Questions, and the Need for a Unified Approach
Recent US Gastric Cancer Prevention Recommendations: Advances, Unanswered Questions, and the Need for a Unified Approach Open
In the past year, two major American gastroenterology societies have introduced pivotal updates to their recommendations for gastric cancer (GC) prevention.1–3 The American College of Gastroenterology (ACG) released new guidelines on Helic…
View article: Impact of population screening for Lynch syndrome insights from the All of Us data
Impact of population screening for Lynch syndrome insights from the All of Us data Open
Lynch Syndrome (LS) is a common genetic cancer condition that allows for personalized cancer prevention and early cancer detection in identified gene carriers. We used data from the All of Us (AOU) Research Initiative to assess the prevale…
View article: Cost-Effectiveness of Colorectal Cancer Screening in the Dominican Republic
Cost-Effectiveness of Colorectal Cancer Screening in the Dominican Republic Open
View article: Underreporting of Gastric Intestinal Metaplasia Due to Underutilization of Diagnostic Codes
Underreporting of Gastric Intestinal Metaplasia Due to Underutilization of Diagnostic Codes Open
View article: Initial Diagnostic Strategies for Helicobacter Pylori in Patients With Bleeding Peptic Ulcers Undergoing Endoscopy: A Cost-Effectiveness Analysis
Initial Diagnostic Strategies for Helicobacter Pylori in Patients With Bleeding Peptic Ulcers Undergoing Endoscopy: A Cost-Effectiveness Analysis Open
Our findings suggest that UBT is the cost-effective strategy to identify H. pylori in patients admitted with PUD. Noninvasive H. pylori testing at the point of care or during inpatient admission should be considered, as it presents limited…
View article: Modeling early-onset cancer kinetics to study changes in underlying risk, detection, and impact of population screening
Modeling early-onset cancer kinetics to study changes in underlying risk, detection, and impact of population screening Open
Recent studies have reported increases in early-onset cancer cases (diagnosed under age 50) and raised questions about whether the increase is related to earlier diagnosis from non-specific medical tests as reflected by decreasing tumor-si…
View article: Racial, Ethnic, and Sex Differences in Incidence-Based Mortality of Aggregate Upper Gastrointestinal Cancers
Racial, Ethnic, and Sex Differences in Incidence-Based Mortality of Aggregate Upper Gastrointestinal Cancers Open
INTRODUCTION: Current strategies for upper gastrointestinal (UGI) cancer screening primarily target cancer-specific risk, with the strongest focus on esophageal adenocarcinoma (EAC). However, all UGI cancers are amendable to screening and …
View article: Financial Incentives and Treatment Outcomes in Adolescents With Severe Obesity
Financial Incentives and Treatment Outcomes in Adolescents With Severe Obesity Open
Importance Adolescent severe obesity is usually not effectively treated with traditional lifestyle modification therapy. Meal replacement therapy (MRT) shows short-term efficacy for body mass index (BMI; calculated as weight in kilograms d…
View article: Supplementary Table S4 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Table S4 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
Adverse Events: Grade 2
View article: Supplementary Methods S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Methods S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
supplementary methods: trial administration
View article: Supplementary Table S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Table S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
MDSC Values by Vaccine Immune Response vs. Non-Response
View article: Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
MUC1 expression and immune infiltrate in baseline and recurrent adenoma pairs
View article: Supplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Supplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma Open
Endpoint titers of plasma antibodies at week 12 amongst vaccine responders